Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amarin Permax settlement

Executive Summary

Ivax granted nonexclusive, U.S. sublicense under two patents to market generic version of Permax (pergolide mesylate) beginning Sept. 2 under a patent litigation settlement announced May 13. In exchange, Amarin will receive royalty payments to be shared with Lilly, which licenses the patents to Amarin, from the first six months' gross profit from sales of Ivax' product. Amarin began promoting the Parkinson's drug in 2001 under a deal with Elan, which originally sued Ivax for infringement. The 30-month stay expires in September. Ivax' ANDA received tentative approval in April. Teva, which was not sued for infringement, began marketing generic pergolide mesylate following its ANDA approval in November...

You may also be interested in...



J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Countries Urged To Open Up On Managed Entry Deals

Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.

UsernamePublicRestriction

Register

PS041796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel